Table 3.
Potential targeted therapies in ATLL.
| Putative Targets | Potential Drugs | Active, or Recruiting Trials Including the Potential Drugs |
|---|---|---|
| CCR4 | Mogamulizumab | NCT04185220 |
| PD1/PD-L1 | Pembrolizumab | |
| IRF4 | Lenalidomide | NCT04301076 |
| proteolysis targeting chimera | ||
| EZH1/2 | Valemetostat Tosylate | NCT04102150 |
| Histone deacetylases | Belinostat | NCT02737046 |
| Romidepsin | NCT04639843 | |
| Phosphatidylinositol 3-kinase | Duvelisib | NCT04639843 |
| CD30 | Brentuximab | NCT03113500 |
| Anti-CD30 CAR-T | NCT04008394 | |
| DNA methylation | 5-azacitidine | NCT04639843 |
| OR-2100 | ||
| PRKCB | MS-533 | |
| proteolysis targeting chimera | ||
| MALT1 | JNJ-67856633 | |
| MDM2/MDM4 | ALRN-6924 |